Effects of subinhibitory concentrations of antimicrobial agents on escherichia coli O157:H7 Shiga toxin release and role of the SOS response

Foodborne Pathogens and Disease

Volumn 10, Issue 9, 2013, Pages 805-812

  Nassar, Farah J ^a   Rahal, Elias A ^a   Sabra, Ahmad ^a   Matar, Ghassan M ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; GENTAMICIN; IMIPENEM; LEXA PROTEIN; NORFLOXACIN; RIFAMPICIN; SHIGA TOXIN;

ANTIMICROBIAL THERAPY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DNA SYNTHESIS; ENERGY YIELD; ESCHERICHIA COLI O157; GENE EXPRESSION; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RNA TRANSCRIPTION;

ESCHERICHIA COLI;

ANTI-INFECTIVE AGENTS; AZITHROMYCIN; DNA, BACTERIAL; ESCHERICHIA COLI O157; GENE EXPRESSION REGULATION, BACTERIAL; GENES, BACTERIAL; GENTAMICINS; HUMANS; IMIPENEM; LATEX FIXATION TESTS; MICROBIAL SENSITIVITY TESTS; NORFLOXACIN; PROPHAGES; REAL-TIME POLYMERASE CHAIN REACTION; RIFAMPIN; SHIGA TOXIN; SOS RESPONSE (GENETICS);

EID: 84883379382     PISSN: 15353141     EISSN: 15567125     Source Type: Journal    
DOI: 10.1089/fpd.2013.1510     Document Type: Article

References (34)

1. Ahmad A, Zurek L. Evaluation of the anti-terminator Q933 gene as a marker for Escherichia coli O157:H7 with high Shiga toxin production. Curr Microbiol 2006;53:324-328. [CLSI] Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility for Bacteria that Grow Aerobically, 8th ed. CLSI document M07-A8.
2. Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
3. Foster PL. Stress responses and genetic variation in bacteria. Mutat Res 2005;569:3-11.
4. Foti JJ, Simmons LA, Beuning PJ, Walker GC. Signal Transduction in the Escherichia coli SOS Response. In: Handbook of Cell Signaling, 2nd ed. Ralph AB, Edward AD (eds.). San Diego: Academic Press, 2010, pp. 2127-2136.
5. Galkin VE, Yu X, Bielnicki J, Ndjonka D, Bell CE, Egelman EH. Cleavage of bacteriophage lambda CI repressor involves the recA C-terminal domain. J Mol Biol 2009;385:779-787.
6. Grif K, Dierich MP, Karch H, Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 1998;17:761-766.
7. Herold S, Siebert J, Huber A, Schmidt H. Global expression of prophage genes in Escherichia coli O157:H7 strain EDL933 in response to norfloxacin. Antimicrob Agents Chemother 2005;49:931-944.
8. Janion C. Inducible SOS response system of DNA repair and mutagenesis in Escherichia coli. Int J Biol Sci 2008;4:338-344.
9. Jinneman KC, Yoshitomi KJ, Weagant SD. Multiplex real-time PCR method to identify Shiga toxin genes stx1 and stx2 and Escherichia coli O157:H7/H-serotype. Appl Environ Microbiol 2003;69:6327-6333.
10. Kadurugamuwa JL, Beveridge TJ. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother 1997;40:615-621.
11. Kanbar A, Rahal EA, Matar GM. In vitro inhibition of the expression of Escherichia coli O157:H7 genes encoding the Shiga like toxins by antimicrobial agents: Potential use in the treatment of human infections. J Appl Res Clin Exp Ther 2003;3:137-143.
12. Kimmitt PT, Harwood CR, Barer MR. Toxin gene expression by Shiga toxin-producing Escherichia coli: The role of antibiotics and the bacterial SOS response. Emerg Infect Dis 2000;6:458-465.
13. Kolling GL, Matthews KR. Export of virulence genes and Shiga toxin by membrane vesicles of Escherichia coli O157:H7. Appl Environ Microbiol 1999;65:1843-1848.
14. Lee JH, Stein BD. Antimicrobials effective for inhibition of enterohaemorrhagic Escherichia coli strains O26, O111, and O157 and their effects on Shiga toxin releases. J Microbiol Biotechnol 2009;19:1238-1243.
15. Lejeune JT, Abedon ST, Takemura K, Christie NP, Sreevatsan S. Human Escherichia coli O157:H7 genetic marker in isolates of bovine origin. Emerg Infect Dis 2004;10:1482-1485.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
17. Loś JM, Loś M, Wegrzyn G, Wegrzyn A. Differential efficiency of induction of various lambdoid prophages responsible for production of Shiga toxins in response to different induction agents. Microb Pathog 2009;47:289-298.
18. Matsushiro A, Sato K, Miyamoto H, Yamamura T, Honda T. Induction of prophages of enterohemorrhagic Escherichia coli O157:H7 with norfloxacin. J Bacteriol 1999;181:2257-2260.
19. McGannon CM, Fuller CA, Weiss AA. Different classes of antibiotics differentially influence Shiga toxin production. Antimicrob Agents Chemother 2010;54:3790-3798.
20. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet 1998;352: 1207-1212.
21. Mohsin M, Haque A, Ali A, Sarwar Y, Bashir S, Tariq A, Afzal A, Iftikhar T, Saeed MA. Effects of ampicillin, gentamicin, and cefotaxime on the release of Shiga toxins from Shiga toxin-producing Escherichia coli isolated during a diarrhea episode in Faisalabad, Pakistan. Foodborne Pathog Dis 2010;7:85-90.
22. Ohara T, Kojio S, Taneike I, Nakagawa S, Gondaira F, Tamura Y, Gejyo F, Zhang HM, Yamamoto T. Effects of azithromycin on Shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother 2002; 46:3478-3483.
23. Panos GZ, Betsi GI, Falagas ME. Systematic review: Are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection Aliment Pharmacol Ther 2006;24:731-742.
24. Pedersen MG, Hansen C, Riise E, Persson S, Olsen KE. Subtypespecific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors. J Clin Microbiol 2008;46:2987-2991.
25. Rahal EA, Kazzi N, Kanbar A, Abdelnoor AM, Matar GM. Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected balb/c mice. Int J Antimicrob Agents 2011a;37:135-139.
26. Rahal EA, Kazzi N, Sabra A, Abdelnoor AM, Matar GM. Decrease in Shiga toxin expression using a minimal inhibitory concentration of rifampicin followed by bactericidal gentamicin treatment enhances survival of Escherichia coli O157:H7-infected balb/c mice. Ann Clin Microbiol Antimicrob 2011b;10:34.
27. Rokney A, Kobiler O, Amir A, Court DL, Stavans J, Adhya S, Oppenheim AB. Host responses influence on the induction of lambda prophage. Mol Microbiol 2008;68:29-36.
28. Shilpakala SR, Raghunathan M. Impact of DNA gyrase inhibition by antisense ribozymes on rec A in E. coli. Mol Biol Rep 2009;36:1937-1942.
29. Shimizu T, Ohta Y, Noda M. Shiga toxin 2 is specifically released from bacterial cells by two different mechanisms. Infect Immun 2009;77:2813-2823.
30. Stohl EA, Brockman JP, Burkle KL, Morimatsu K, Kowalczykowski SC, Seifert HS. Escherichia coli RecX inhibits RecA recombinase and coprotease activities in vitro and in vivo. J Biol Chem 2003;278:2278-2285.
31. Wegrzyn A, Szalewska-Palasz A, Blaszczak A, Liberek K, Wegrzyn G. Differential inhibition of transcription from sigma70-and sigma32-dependent promoters by rifampicin. Febs Lett 1998;440:172-174.
32. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli o157:H7 infections. N Engl J Med 2000;342: 1930-1936.
33. Yarnell WS, Roberts JW. The phage lambda gene Q transcription antiterminator binds DNA in the late gene promoter as it modifies RNA polymerase. Cell 1992;69:1181-1189.
34. Zhang Q, Donohue-Rolfe A, Krautz-Peterson G, Sevo M, Parry N, Abeijon C, Tzipori S. Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis 2009;199:486-493.